Background Image
Previous Page  167 / 182 Next Page
Information
Show Menu
Previous Page 167 / 182 Next Page
Page Background

166

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

184

Mercadanti S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and

treatment. Cancer Treatment Reviews 1998; 24: 425-432.

185

Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health

Organization analgesic ladder? Cancer Control 2000; 7: 149-156.

186

Müller-Schwefe GHH (Hrsg.). Schnellwirksames Fentanyl in der Therapie von Durch-

bruchschmerzen onkologischer Patienten. Thieme Praxis Report 2011; 3(5): 1-16.

187

Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl cit-

rate for the treatment of breakthrough pain in cancer patients: an overview of its phar-

macological and clinical characteristics. Am J Hosp Palliat Care 2005; 22(3): 228-232.

188

Mystakidou K, Panagiotou I, Gouliamos A. Fentanyl nasal spray for the treatment of

cancer pain. Expert Opin Pharmacother 2011; 12(10): 1653-1659.

189

Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J. Long-term

effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the

treatment of breakthrough cancer pain. Curr Med Res Opin 2011; 27(3): 519-530.

190

Nalamachu SR, Rauck RL, Wallace MS, Hassman D, Howell J. Successful dose finding

with sublingual fentanyl tablet: combined results from 2 open-label titration studies.

Pain Pract 2012; 12(6): 449-456.

191

National Cancer Institute. Comprehensive Cancer Information.

http://www.nci.nih.gov/

cancertopics/pdq/supportivecare/pain/healthprofessional (aufgerufen am 31.10.2012).

192

Nauck F, Eulitz N. Cancer pain management. Basic therapy and treatment of breakt-

hrough pain. Schmerz 2007; 21(4): 359-370.

193

Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwöhner K,

Schulenberg D, Radbruch L; Working Group on the Core Documentation for Palliative

Care Units in Germany. Drugs in palliative care: results from a representative survey in

Germany. Palliat Med 2004; 18(2): 100-107.

194

Nave R, Connolly SM, Popper L, Lahu G, Schmitt H. Single-dose and multi-dose delivery

systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate

pharmacokinetic study. Int J Clin Pharmacol Ther. 2012; 50(10): 751-759.

195

Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal

fentanyl spray (INFS) in subjects with common cold. Eur J Pain 2009a; 13 (Suppl. 1):

S207.

196

Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal

fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior

administration of oxymetazoline. Eur J Pain 2009b; 13 (Suppl 1): S207.

197

Nicholson B, Agarwala SS. Opioid delivery in the treatment of cancer breakthrough

pain: a review of routes of administration. J Opioid Manag 2011; 7(1): 69-79.

198

Núñez-Olarte JM, Alvarez-Jiménez P. Emerging opioid abuse in terminal cancer patients

taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Mana-

ge 2011; 42(6): e6-8.

Literaturverzeichnis